Search: WFRF:(Rudenstam Carl Magnus 1930)
> (1995-1999) >
Efficacy of pamidro...
-
Hultborn, Ragnar,1946Gothenburg University,Göteborgs universitet,Institutionen för särskilda specialiteter, Avdelningen för onkologi,Institute of Selected Clinical Sciences, Department of Oncology
(author)
Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study
- Article/chapterEnglish1999
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/45511
-
https://gup.ub.gu.se/publication/45511URI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
PURPOSE: To evaluate the efficacy of pamidronate 60 mg i.v. q 4 weeks in women with advanced breast cancer with skeletal metastases. PATIENTS AND METHODS: 404 woman with skeletal metastases from breast cancer in Sweden and Norway were included in a randomized, placebo-controlled, multicenter study. Except for the study medication, other palliative treatment was chosen at the discretion of the physician. Skeletal related events, i.e. increased pain, treatment of hypercalcemia, pathologic fractures of long bones or pelvis, paralyses due to vertebral compression, palliative radiotherapy for skeletal metastases, surgery on bone and change of antitumor therapy were recorded every third month as well as a self-estimated pain-score using visual Analog Scales and analgesic consumption. RESULTS: There was a significantly increased time to progression of pain (p < 0.01), to hypercalcemic events (p < 0.05) as well as for the cumulative number of skeletal related events (p < 0.01) in favor for the pamidronate group. No statistically significant reduction of pathologic fractures of long bones or pelvis, or pareses due to vertebral compression occurred. No statistically significant differences were found for the need of radiotherapy and surgery on bone. The pamidronate group faired better regarding performance status (p < 0.05). There was a statistically not significant lower consumption of opioid analgesics in the pamidronate group (p = 0.14). CONCLUSION: Pamidronate 60 mg i.v. q 4 weeks reduces skeletal events and improves the quality of life in women with bone metastases from breast cancer.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Gundersen, S.
(author)
-
Ryden, S.
(author)
-
Holmberg, E.
(author)
-
Carstensen, J.
(author)
-
Wallgren, U. B.
(author)
-
Killany, S.
(author)
-
Andreassen, L.
(author)
-
Carlsson, G.
(author)
-
Fahl, N.
(author)
-
Hatschek, T.
(author)
-
Sommer, H. H.
(author)
-
Hessman, Y.
(author)
-
Hornmark-Stenstam, B.
(author)
-
Johnsborg, S.
(author)
-
Klepp, R.
(author)
-
Laino, R.
(author)
-
Niklasson, L. G.
(author)
-
Rudenstam, Carl-Magnus,1930Gothenburg University,Göteborgs universitet,Institutionen för de kirurgiska disciplinerna,Institute of Surgical Sciences
(author)
-
Sundbeck, A.
(author)
-
Soderberg, M.
(author)
-
Tejler, G.
(author)
-
Göteborgs universitetInstitutionen för särskilda specialiteter, Avdelningen för onkologi
(creator_code:org_t)
Related titles
-
In:Anticancer Res19:4C, s. 3383-920250-7005
Internet link
Find in a library
To the university's database
- By the author/editor
-
Hultborn, Ragnar ...
-
Gundersen, S.
-
Ryden, S.
-
Holmberg, E.
-
Carstensen, J.
-
Wallgren, U. B.
-
show more...
-
Killany, S.
-
Andreassen, L.
-
Carlsson, G.
-
Fahl, N.
-
Hatschek, T.
-
Sommer, H. H.
-
Hessman, Y.
-
Hornmark-Stensta ...
-
Johnsborg, S.
-
Klepp, R.
-
Laino, R.
-
Niklasson, L. G.
-
Rudenstam, Carl- ...
-
Sundbeck, A.
-
Soderberg, M.
-
Tejler, G.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Anticancer Res
- By the university
-
University of Gothenburg